Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Prostate Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/14/2019 |
Start Date: | December 23, 2010 |
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206
works in treating patients with previously treated prostate cancer. Androgens can cause the
growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the
amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. It is not yet known whether
bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate
cancer.
works in treating patients with previously treated prostate cancer. Androgens can cause the
growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the
amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. It is not yet known whether
bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate
cancer.
PRIMARY OBJECTIVES:
I. To compare the two regimens on the proportion of patients with undetectable
prostate-specific antigen (PSA) level (< 0.2 ng/mL) at 44 weeks.
SECONDARY OBJECTIVES:
I. To assess the proportion of patients with PSA decline >= 85% at 44 weeks on the
combination therapy arm compared to that of bicalutamide monotherapy arm.
II. To assess the distribution of best PSA response in each study arm. III. To assess the
time to PSA progression in each arm of the study. IV. To assess the time to PSA nadir in each
arm of the study. V. To assess the duration of PSA response in each arm of the study. VI. To
characterize the PSA slope pre-study, during treatment, and off treatment.
VII. To evaluate the safety and tolerability of MK-2206 (Akt inhibitor MK2206) in this
patient population.
VIII. To determine whether Gleason score has any effect on PSA response to treatment.
IX. To determine whether prior hormonal therapy has any effect on PSA response to treatment.
TERTIARY OBJECTIVES:
I. Samples of the primary tumor specimen will be retrieved for banking and future analysis of
the molecular profile of the primary prostate cancer (PC) tissues with emphasis on the
androgen receptor (AR) and protein kinase B (Akt) upstream and downstream signaling pathways.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients undergo observation on weeks 1-12. Patients then receive bicalutamide* orally
(PO) once daily (QD) on weeks 13-44. Patients with a PSA decline of >= 50% may continue on
bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive Akt inhibitor MK2206** PO once per week on weeks 1-44 and
bicalutamide* PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on
MK2206 and bicalutamide until week 72 in the absence of disease progression or unacceptable
toxicity.
NOTE: *Patients may begin bicalutamide on weeks 4-11 if the disease worsens.
NOTE: **Patients on Akt inhibitor MK2206 with a PSA < 0.2 ng/mL by week 12 do not receive
bicalutamide until PSA rises to >= 0.2 ng/mL.
After completion of study therapy, patients are followed up every 3 months for 2 years, every
6 months for 3 years, and then every year for up to 10 years.
I. To compare the two regimens on the proportion of patients with undetectable
prostate-specific antigen (PSA) level (< 0.2 ng/mL) at 44 weeks.
SECONDARY OBJECTIVES:
I. To assess the proportion of patients with PSA decline >= 85% at 44 weeks on the
combination therapy arm compared to that of bicalutamide monotherapy arm.
II. To assess the distribution of best PSA response in each study arm. III. To assess the
time to PSA progression in each arm of the study. IV. To assess the time to PSA nadir in each
arm of the study. V. To assess the duration of PSA response in each arm of the study. VI. To
characterize the PSA slope pre-study, during treatment, and off treatment.
VII. To evaluate the safety and tolerability of MK-2206 (Akt inhibitor MK2206) in this
patient population.
VIII. To determine whether Gleason score has any effect on PSA response to treatment.
IX. To determine whether prior hormonal therapy has any effect on PSA response to treatment.
TERTIARY OBJECTIVES:
I. Samples of the primary tumor specimen will be retrieved for banking and future analysis of
the molecular profile of the primary prostate cancer (PC) tissues with emphasis on the
androgen receptor (AR) and protein kinase B (Akt) upstream and downstream signaling pathways.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients undergo observation on weeks 1-12. Patients then receive bicalutamide* orally
(PO) once daily (QD) on weeks 13-44. Patients with a PSA decline of >= 50% may continue on
bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive Akt inhibitor MK2206** PO once per week on weeks 1-44 and
bicalutamide* PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on
MK2206 and bicalutamide until week 72 in the absence of disease progression or unacceptable
toxicity.
NOTE: *Patients may begin bicalutamide on weeks 4-11 if the disease worsens.
NOTE: **Patients on Akt inhibitor MK2206 with a PSA < 0.2 ng/mL by week 12 do not receive
bicalutamide until PSA rises to >= 0.2 ng/mL.
After completion of study therapy, patients are followed up every 3 months for 2 years, every
6 months for 3 years, and then every year for up to 10 years.
Inclusion Criteria:
- Patient must have histologically confirmed diagnosis of prostate cancer
- Patient must have had previous treatment with definitive surgery or radiation therapy
or cryoablation
- Patient may have prior salvage therapy (surgery, radiation or other local ablative
procedures) within 4 weeks prior to randomization if the intent was for cure;
prophylactic radiotherapy to prevent gynecomastia within 4 weeks prior to
randomization is allowed
- Patient must have no evidence of metastatic disease on physical exam, computed
tomography (CT) abdomen/pelvis (or magnetic resonance imaging [MRI]), chest x-ray (or
CT chest) and bone scan within 8 weeks prior to randomization
- Patient may have had prior neoadjuvant and/or adjuvant therapy (chemotherapy, vaccines
or experimental agents) within 4 weeks prior to randomization, if the PSA rise and PSA
doubling time (PSADT) were documented after the testosterone level was > 150 ng/dL
- Patient may not have had therapy modulating testosterone levels (such as
luteinizing-hormone, releasing-hormone agonists/antagonists and antiandrogens) within
1 year prior to randomization, unless it was in the neoadjuvant and/or adjuvant
setting; agents such as 5 alpha reductase inhibitors, ketoconazole, abiraterone,
systemic steroids, or herbal supplements known to decrease PSA levels including any
dose of megestrol acetate, finasteride (e.g., Saw Palmetto and PC-SPES, African pygeum
extract, lycopene, alanine, glutamic acid and glycine, beta-sitosterol, lycopene,
nettle root extract, quercitin, Belizian Man Vine extract, mulra puama extract and
epimedium extract campesterol, beta-sitosterol, stigmasterol, sitostanol and
brassicasterol) are not permitted at any time during the period that the PSA values
are being collected
- Patient must have hormone-sensitive prostate cancer as evident by a serum total
testosterone level > 150 ng/dL within 12 weeks prior to randomization
- Patient must have evidence of biochemical failure after primary therapy and subsequent
progression
- Biochemical failure is declared when the PSA reaches a threshold value after
primary treatment and it differs for radical prostatectomy or radiation therapy
- For radical prostatectomy the threshold for this study is PSA >= 0.4 ng/mL
- For radiation therapy the threshold is a PSA rise of 2 ng/mL above the nadir PSA
achieved post radiation with or without hormone therapy (2006 Radiation Therapy
Oncology Group [RTOG]-American Society for Radiation Oncology [ASTRO] Consensus
definition)
- PSA progression requires a PSA rise above the threshold (PSA1) measured at any
time point since the threshold was reached
- The PSADT must be < 12 months; requires two consecutive PSA rises (PSA2 and PSA3)
above the PSA1; PSA2 and PSA3 must be obtained within 6 months of study entry;
all baseline PSAs should be obtained, preferably, at the same reference lab
- PSADT calculation needs 3 PSA values:
- PSA1 is any PSA value that is equal or greater than the threshold PSA (0.4 ng/mL
for radical prostatectomy or 2 ng/mL above the nadir for primary radiation
therapy) indicating biochemical relapse
- PSA2 must be higher than PSA1, obtained at least 2 weeks after PSA1 and within 6
months or less from randomization
- PSA3 must be higher than PSA2 and obtained at least 2 weeks after PSA2
- Baseline PSA must have reached a minimum of 2 ng/mL but be no greater than 50
ng/mL and equal or higher than PSA3; PSA3 may be used as baseline PSA if obtained
within 1 week of randomization
- Patient's PSA doubling time (PSADT) must be less than 12 months
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0
or 1
- Granulocytes >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Serum creatinine within normal institutional limits or creatinine clearance >= 50
ml/min for patients with creatinine levels above institutional normal
- Serum total bilirubin =< 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase (ALP) =< 2.5 x ULN
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and
serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x
institutional upper limit of normal
- Human immunodeficiency virus (HIV)-positive patients are excluded from this study
- Patient cannot receive concurrent therapeutic administration of anticoagulant therapy;
low dosage aspirin =< 325 mg per day is allowed
- Patients with impaired cardiac function including any one of the following will be
excluded from entry on study:
- Baseline corrected QT interval (QTc) > 450 msec (male) (patients with QTc 450-480
msec will be allowed to participate in this trial if they do not have any of the
other cardiac conditions mentioned in this section)
- Patients with congenital long QT syndrome
- History of sustained ventricular tachycardia
- Any history of ventricular fibrillation or torsades de pointes
- Concomitant use of drugs with a risk of causing torsades de pointes
- Bradycardia defined as heart rate < 50 beats per minute; patients with a
pacemaker and heart rate >= 50 beats per minute are eligible
- Myocardial infarction or unstable angina within 6 months of study entry
- Congestive heart failure (New York Heart Association class III or IV)
- Right bundle branch block and left anterior hemi-block (bifascicular block)
- Patient must not have gastrointestinal (GI) tract disease resulting in an inability to
take oral medication, malabsorption syndrome, a requirement for intravenous (IV)
alimentation, prior surgical procedures affecting absorption, uncontrolled
inflammatory GI disease (e.g., Crohn's, ulcerative colitis)
- Patient may not be receiving any other investigational agents or receiving concurrent
anticancer therapy (chemotherapy, immunotherapy, radiation therapy, surgery for
cancer, or experimental medications) at time of randomization
- Patient may not have a history of allergic reactions attributed to compounds of
similar chemical or biologic composition to MK-2206 or bicalutamide
- Patient must not have any uncontrolled intercurrent illness including, but not limited
to, ongoing or active infection, cardiac arrhythmia, or psychiatric illness/social
situations that would limit compliance with study requirements
- Patients with diabetes or at risk for hyperglycemia MUST not be excluded from trials
with MK-2206, but the hyperglycemia should be well controlled before the patient
enters the trial
- Patients receiving any medications or substances that are inhibitors or inducers of
cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible
- Patient must NOT have previous or concurrent malignancy; exceptions are made for
patients who meet any of the following conditions:
- Basal cell or squamous cell carcinoma of the skin OR
- Prior malignancy has been adequately treated and patient has been continuously
disease free for >= 2 years
- Patient must agree to use barrier contraception during and for 3 months after
discontinuation of study treatment; if patient impregnates a woman while on treatment
or within 3 months of discontinuing treatment, he should inform his treating physician
immediately
- Patients must discontinue use of enzyme-inducing anti-epileptic drugs (EIAEDs) >= 14
days prior to study enrollment; the investigator may prescribe non-EIAEDs; patients
who must begin EIAED therapy while on study will be allowed to remain
- Patients must not be taking cytochrome P450 enzyme-inducing antiepileptic drugs
(phenytoin, carbamazepine or phenobarbital), St John's Wort, ketoconazole,
dexamethasone, the dysrhythmic drugs (terfenadine, quinidine, procainamide, sotalol,
probucol, bepridil, indapamide or flecainide), haloperidol, risperidone, rifampin,
grapefruit, or grapefruit juice within two weeks of randomization and during the
course of therapy
- Patients may have received targeted agents (angiogenesis inhibitors, epidermal growth
factor receptor [EGFR] inhibitors, mammalian target of rapamycin [mTOR] inhibitors,
phosphatidylinositol 3 kinase [PI3K] inhibitors, etc.), however patients must have
discontinued treatment with the targeted agent(s) at least 4 weeks prior to
enrollment; if the patient stopped targeted agent(s) due to unresolved or persistent
grade 3 or 4 toxicity, patient cannot be enrolled onto the study regardless of the
length of time since discontinuation of treatment with targeted agent(s)
We found this trial at
193
sites
North Colorado Medical Center NCMC is a fully accredited, private, non-profit facility licensed to operate...
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
Click here to add this to my saved trials
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Toledo Clinic Cancer Centers-Bowling Green Our doctors evaluate and make recommendations regarding cancer treatment for...
Click here to add this to my saved trials
Click here to add this to my saved trials
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
Memorial Hospital Memorial Hospital is a vital force in establishing and maintaining the well-being of...
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 864-6000
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
Click here to add this to my saved trials
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
Click here to add this to my saved trials
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
Click here to add this to my saved trials
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
Rose Medical Center Well known as a Denver institution and a 9th Avenue landmark for...
Click here to add this to my saved trials
Porter Adventist Hospital Founded in 1930, Porter Adventist Hospital has provided people throughout Denver and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mercy Medical Center - Des Moines Mercy Medical Center
Click here to add this to my saved trials
Click here to add this to my saved trials
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Iowa Lutheran Hospital Iowa Lutheran Hospital has a long history of serving the Des Moines...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
Click here to add this to my saved trials
Elkhart General Hospital For over 100 years, the highly skilled professionals of Elkhart General Hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Genesys Hurley Cancer Institute Bringing the most advanced cancer treatment services, technologies and programs available...
Click here to add this to my saved trials
420 S Saginaw St
Flint, Michigan 48502
Flint, Michigan 48502
810-232-3522
Genesys Regional Medical Center-West Flint Campus The health care team at Genesys Downtown Flint Health...
Click here to add this to my saved trials
Poudre Valley Hospital A 270-bed regional medical center offering a wide array of treatments, surgeries,...
Click here to add this to my saved trials
Fredericksburg Oncology Inc Fredericksburg Oncology is dedicated to offering each patient individual care and attention...
Click here to add this to my saved trials
Unity Hospital Unity Hospital is one of the Twin Cities
Click here to add this to my saved trials
Illinois CancerCare - Galesburg Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
4300 Londonderry Road
Harrisburg, Pennsylvania 17109
Harrisburg, Pennsylvania 17109
Click here to add this to my saved trials
Click here to add this to my saved trials
Mason District Hospital Mason District Hospital is dedicated to providing superior healthcare close to home...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Hutchinson Area Health Care Hutchinson Health is a team of medical professionals and support staff...
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Allegiance Health Allegiance Health is a community-owned and locally-governed health system in Jackson, Michigan. We...
Click here to add this to my saved trials
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
Click here to add this to my saved trials
Borgess Medical Center At Borgess, healing is our calling. This is the place where people...
Click here to add this to my saved trials
Community Howard Regional Health Selecting quality health care services for yourself, a relative or friend...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Sparrow Hospital Sparrow has grown to become the region's largest health system, and its diverse...
Click here to add this to my saved trials
Click here to add this to my saved trials
601 South Rancho Drive
Suite C-26
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
(702) 384-0013
Nevada Cancer Research Foundation CCOP The Nevada Cancer Research Foundation Community Clinical Oncology Program (NCRF-CCOP)...
Click here to add this to my saved trials
Beebe Medical Center Located in beautiful historic Lewes, Delaware, near Rehoboth Beach, Beebe Healthcare offers...
Click here to add this to my saved trials
Lima Memorial Hospital We also offer an extended network of primary care, pediatric and specialist...
Click here to add this to my saved trials
Littleton Adventist Hospital On April 3, 1989 Littleton Adventist Hospital opened its doors to the...
Click here to add this to my saved trials
Click here to add this to my saved trials